Table 1.
Type-specific HPV prevalences at baseline enrollment in the population-based trial of concomitant HPV vaccination and HPV screening
| Birth year | Number of women in population |
Prior Vaccination offered |
n (%) of those women vaccinated in trial |
n (%) of those women HPV tested |
HPV 16 | HPV18 | HPV45 | HPV 33/58 | HPV 31 | HPV 52 | Low oncogenic HPV (35/39/51/56/59/66/68) | Other HPVa | HPV neg | n (%) with valid HPV test |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | ||||||||
| 1994 | 18,436 | Catch-up | 5687 | 4941 | 122 | 26 | 118 | 191 | 106 | 117 | 475 | 136 | 3609 | 4900 |
| (30.85) | (86.88) | (2.47) | (0.53) | (2.39) | (3.87) | (2.15) | (2.37) | (9.61) | (2.75) | (73.04) | (99.17) | |||
| 1995 | 16,761 | Catch-up | 5120 | 4428 | 98 | 24 | 148 | 170 | 98 | 126 | 456 | 92 | 3175 | 4387 |
| (30.55) | (86.48) | (2.21) | (0.54) | (3.34) | (3.84) | (2.21) | (2.85) | (10.30) | (2.08) | (71.70) | (99.07) | |||
| 1996 | 15,619 | Catch-up | 4788 | 4176 | 72 | 18 | 118 | 138 | 74 | 131 | 421 | 161 | 3012 | 4145 |
| (30.65) | (87.22) | (1.72) | (0.43) | (2.83) | (3.30) | (1.77) | (3.14) | (10.08) | (3.86) | (72.13) | (99.26) | |||
| 1997 | 13,971 | Catch-up | 4108 | 3465 | 73 | 26 | 93 | 143 | 65 | 97 | 372 | 164 | 2405 | 3438 |
| (29.40) | (84.35) | (2.11) | (0.75) | (2.68) | (4.13) | (1.88) | (2.80) | (10.74) | (4.73) | (69.41) | (99.22) | |||
| 1998 | 12,802 | Catch-up | 4020 | 3419 | 73 | 16 | 67 | 125 | 41 | 77 | 270 | 425 | 2303 | 3997 |
| (31.40) | (85.05) | (2.14) | (0.47) | (1.96) | (3.66) | (1.20) | (2.25) | (7.90) | (12.43) | (67.36) | (99.43) | |||
| 1999 | 11,801 | School-based | 2382 | 2128 | 15 | 1 | 34 | 92 | 22 | 81 | 246 | 39 | 1584 | 2368 |
| (20.18) | (89.34) | (0.70) | (0.05) | (1.60) | (4.32) | (1.03) | (3.81) | (11.56) | (1.83) | (74.44) | (99.41) | |||
| Total | 89,390 | – | 26,105 | 22,557 | 453 | 111 | 578 | 859 | 406 | 629 | 2240 | 1017 | 16,088 | 22,381 |
| (29.20) | (86.41) | (2.01) | (0.49) | (2.56) | (3.81) | (1.80) | (2.79) | (9.93) | (4.51) | (71.32) | (99.22) |
a“Other HPV” corresponds to the results obtained as a pool from the Cobas platform (HPV types 31/33/35/39/45/51/52/56/58/59/66/68) that could not be retested in the BD platform for extended genotyping (i.e., the exact genotype is unknown). Comparison can also be made to population-based HPV prevalences in Sweden in these age groups at the time when no HPV vaccination had been offered. This has been previously published and was 30% for any HPV positivity, 6.1% for HPV 16, and 2.4% for HPV 188.